Follow-The-Filings

Security · featured owners

CLDX Celldex Therapeutics Inc. New

Health Care COM NEW Equity as of 2026 Q2 among managers we track

  • 2 Owners
  • Max 2.1%
  • $17M
  • 1 add

CLDX (Celldex Therapeutics Inc. New) is held in 2 featured 13F books as of 2026 Q2. Palo Alto Investors is the largest tracked holder by portfolio weight (2.1%). Figures are as-filed 13F, not free float.

Who owns this now

Largest portfolio weights among featured holders · max 2.1% (Palo Alto Investors) · not free-float ownership

  1. Palo Alto Investors add 2.1%
  2. Nathan Fischel 0.49%

holders

sorted by value · long equity only · current book 2026 Q2 · open a manager for their book

history
Palo Alto Investors 2026 Q2 2.1% Add +34.9% 399,856 $15M history
Nathan Fischel - Dafna Capital Management 2026 Q2 0.49% Hold 68,518 $3M history

2 current · options excluded

SEC filings

Recent issuer filings from EDGAR · 16 shown · open Filing / Doc on SEC.gov

Filed Form Detail Links
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 5.02,9.01 Filing Doc
8-K 5.02,5.07,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 1.01,8.01,9.01 Filing Doc
424B5 Filing Doc
424B5 Filing Doc
8-K 2.02,9.01 Filing Doc
10-K Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc
8-K 8.01,9.01 Filing Doc
8-K 2.02,9.01 Filing Doc
10-Q Filing Doc

Insider forms

Form 3 / 4 / 5 from EDGAR · 7 rows shown

Filed Form Detail Links
4 Period Jun 25, 2026 · 18 forms Filing Doc
4 Period Jan 2, 2026 Filing Doc
4 Period Dec 15, 2025 Filing Doc
4 Period Dec 4, 2025 Filing Doc
4 Period Nov 13, 2025 Filing Doc
4 Period Nov 10, 2025 Filing Doc
4 Period Aug 13, 2025 Filing Doc

Updated about 23 hours ago Source: SEC EDGAR submissions All on EDGAR

financials

US-GAAP annual · as tagged in Form 10-K · fiscal years · values link to the SEC filing

Income statement

Metric FY2023 FY2024 FY2025
Revenue $6.88M $7.02M $1.54M
Gross profit * $6.58M $6.82M $1.34M
Gross margin * 95.6% 97.2% 87.1%
Net income — — -$258.76M
Net margin * — — -16748.0%

Balance sheet

Metric FY2023 FY2024 FY2025
Total current assets $431.69M $747.16M $534.66M
Total non-current assets * $33.93M $45.18M $48.32M
Total assets $465.63M $792.34M $582.98M
Total current liabilities $31.12M $39.5M $50.99M
Total non-current liabilities * $5.33M $5.83M $4.83M
Total equity $429.17M $747M $527.16M

Cash flow

Metric FY2023 FY2024 FY2025
Cash from operations -$107.29M -$157.78M -$210.94M
Cash from investing -$105.78M -$290.13M $209.07M
Cash from financing $218.46M $441.45M $2.39M
Net change in cash $5.38M -$6.46M $0.515M

Source: SEC companyfacts (US-GAAP 10-K) · * = computed (not a single XBRL tag) · fiscal year as labeled by the issuer · not adjusted or audited by Follow-The-Filings

ownership over time

filing count by report period · click a bar for that quarter’s holders